Weiss Asset Management LP acquired a new position in shares of Amgen Inc. (NASDAQ:AMGN – Get Rating) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm acquired 16,050 shares of the medical research company’s stock, valued at approximately $3,618,000.
A number of other institutional investors and hedge funds have also bought and sold shares of AMGN. FMR LLC increased its stake in shares of Amgen by 24.9% during the second quarter. FMR LLC now owns 8,911,384 shares of the medical research company’s stock valued at $2,168,140,000 after buying an additional 1,774,223 shares during the period. Vanguard Group Inc. increased its position in Amgen by 2.8% during the 3rd quarter. Vanguard Group Inc. now owns 47,459,511 shares of the medical research company’s stock valued at $10,697,373,000 after purchasing an additional 1,310,894 shares during the period. Renaissance Technologies LLC raised its holdings in shares of Amgen by 279.3% in the 2nd quarter. Renaissance Technologies LLC now owns 1,439,745 shares of the medical research company’s stock valued at $350,290,000 after purchasing an additional 1,060,200 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its position in shares of Amgen by 164.9% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,337,970 shares of the medical research company’s stock worth $323,548,000 after purchasing an additional 832,885 shares during the period. Finally, Robeco Institutional Asset Management B.V. boosted its stake in shares of Amgen by 84.5% during the third quarter. Robeco Institutional Asset Management B.V. now owns 1,201,655 shares of the medical research company’s stock valued at $270,853,000 after purchasing an additional 550,439 shares in the last quarter. 75.53% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
Several analysts have issued reports on the company. Truist Financial dropped their target price on Amgen from $280.00 to $260.00 and set a “buy” rating on the stock in a research report on Monday, February 13th. SVB Leerink cut their target price on Amgen from $282.00 to $267.00 and set a “market perform” rating on the stock in a research note on Thursday, February 2nd. StockNews.com assumed coverage on shares of Amgen in a research report on Thursday. They set a “strong-buy” rating for the company. Cowen lowered their price target on shares of Amgen from $307.00 to $289.00 and set an “outperform” rating on the stock in a report on Wednesday, February 1st. Finally, Royal Bank of Canada reduced their price objective on shares of Amgen from $268.00 to $258.00 and set a “sector perform” rating for the company in a research note on Wednesday, February 1st. Four investment analysts have rated the stock with a sell rating, three have assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Amgen currently has an average rating of “Hold” and an average target price of $251.44.
Amgen Stock Down 2.0 %
Amgen (NASDAQ:AMGN – Get Rating) last issued its earnings results on Tuesday, February 7th. The medical research company reported $4.09 EPS for the quarter, beating analysts’ consensus estimates of $4.04 by $0.05. Amgen had a return on equity of 359.47% and a net margin of 24.89%. The firm had revenue of $6.84 billion for the quarter, compared to analyst estimates of $6.77 billion. During the same quarter in the prior year, the firm earned $4.36 earnings per share. Amgen’s revenue for the quarter was down .1% on a year-over-year basis. Equities analysts anticipate that Amgen Inc. will post 17.72 EPS for the current year.
Amgen Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 8th. Investors of record on Thursday, May 18th will be issued a dividend of $2.13 per share. The ex-dividend date is Wednesday, May 17th. This represents a $8.52 annualized dividend and a dividend yield of 3.71%. Amgen’s dividend payout ratio (DPR) is presently 70.36%.
Amgen, Inc is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.
- Get a free copy of the StockNews.com research report on Amgen (AMGN)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Get Rating).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.